FIELD: pharmaceuticals.
SUBSTANCE: invention relates to an inhibitor that is a pyridazine derivative, namely a compound of formula (V), its stereoisomer or a pharmaceutically acceptable salt thereof, where R9 is C3-6 cycloalkyl, R is C1-6 alkoxy, R3 is selected from a group consisting of hydrogen and halogen, R4 is cyclopropyl, R5 and R6 are hydrogen, x is either 0 or 1. The invention also relates to a method of producing a compound of formula (V), to a pharmaceutical composition containing it and to its use for the production of a TYK2 inhibitory medicinal product for the treatment of an inflammatory disease and an autoimmune disease, wherein the inflammatory disease and the autoimmune disease are selected from the group consisting of rheumatoid arthritis, dermatitis, psoriasis and inflammatory bowel disease.
EFFECT: development of a safer selective TYK2 inhibitor for the treatment of inflammatory and autoimmune diseases.
10 cl, 1 dwg, 121 ex, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| INHIBITOR CONTAINING BICYCLIC DERIVATIVE, METHOD OF PREPARATION AND USE THEREOF | 2020 |
|
RU2820948C2 |
| REGULATORS OF DERIVATIVES OF STEROIDS, METHODS OF THEIR OBTAINING AND USE | 2019 |
|
RU2803499C1 |
| INHIBITOR CONTAINING A TRICYCLIC DERIVATIVE, A METHOD OF ITS PRODUCTION AND ITS USE | 2019 |
|
RU2800543C2 |
| REGULATORS-DERIVATIVES OF STEROIDS, METHODS OF THEIR OBTAINING AND THEIR USE | 2019 |
|
RU2797408C2 |
| INHIBITOR OF EGFR AND PRODUCTION AND USE THEREOF | 2015 |
|
RU2702631C2 |
| MACROCYCLIC TYROSINE KINASE INHIBITOR AND ITS USE | 2019 |
|
RU2798231C2 |
| HETEROAROMATIC COMPOUNDS AS PHOSPHATIDYLINOSITOL 3-KINASE MODULATORS AND METHODS OF USE | 2013 |
|
RU2665036C9 |
| DERIVATIVE OF 6-OXO-1,6-DIHYDROPYRIDAZINE, METHOD FOR PRODUCTION THEREOF AND APPLICATION THEREOF IN MEDICINE | 2020 |
|
RU2791534C2 |
| DERIVATIVES OF SUBSTITUTED TRIAZOLDIAMINE, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD FOR ITS PREPARING | 2001 |
|
RU2274639C2 |
| CERTAIN PROTEIN KINASE INHIBITORS | 2015 |
|
RU2671494C2 |
